辛伐他汀对冠心病患者血浆一氧化氮、一氧化氮合酶的影响

Effect of Simvastatin on blood lipid and plasma NO and NOS in patients with coronary artery disease

目的探讨辛伐他汀对冠心病患者血浆NO和NOS的影响。方法将98例冠心病住院患者随机分为常规治疗组、辛伐他汀组及联合治疗组,采用硝酸还原酶法,在治疗前后抽血检测血中NO和NOS水平。结果各组冠心病患者在8周前,其血浆NO和NOS水平没有差异(F=4.86,3.53P>0.05),在治疗8周后存在着明显的差异(F=17.63,11.07P<0.05),各组在治疗后血浆NO和NOS水平均明显增高,以联合治疗组增高最明显,其次是辛伐他汀组和常规治疗组。结论辛伐他汀可通过增加血浆NO和NOS的浓度来改善冠心病患者的血管内皮功能,该作用可能是通心络防治冠心病的机制之一。

Objective Observe effects of Simvastatin on NO and NOS in plasma of patients with coronary heart disease. Methods 98 patients with coronary artery disease patients were randomly divided into conventional therapy group, Simvastatin group and therapeutic alliance group, adopt nitrate reductase for detecting plasma adiponectin and leptin levels before and after treatment. Results Eight weeks ago, there was no difference of NO and NOS levels in plasma of patients with coronary heart disease before treatment（ F =4. 86,3.53 P 〉 0.05 ）. 8 weeks later, there was a evident difference of NO and NOS levels in plasma of patients with coro- nary heart disease after treatment. NO and NOS levels in plasma of therapeutic （F = 17. 63,11.07 P 〈 0. 05 ） , alliance group increased significantly in therapeutic alliance group, followed by Simvastatin group and the conventional therapy group. Conclusion Simvastatin has beneficial effects on improving the impaired endothelium-dependent vasodilatation and increasing serum NO and NOS, and this may be one of mechanisms for the beneficial efects of simavastatin in prevention and treatment of CAD.